Literature DB >> 1270806

Receptors for immune complexes on cells within a non-lymphoid murine tumor.

G R Braslawsky, M Yaackubowicz, A Frensdorff, I P Witz.   

Abstract

In this paper we present evidence that antibodies unrelated to the tumor cell can comprise part of the in vivo Ig surface coat of cells derived from the non-lymphoid murine tumor, TA3/St. This was shown by incubating TA3 cells originating from other OA or BSA preimmunized mice with radioiodinated 125I-OA and 131I BSA. Radioiodine-labeled 125I-OA specifically fixed to cells derived from TA3/St tumors originating from OA-preimmunized mice. On the other hand 131I-BSA was specifically fixed by cell populations from BSA-preimmunized mice. Incubation of these cells in vitro at 37 degrees C abolished the specific binding and antibody could subsequently be detected in the tissue culture medium. Radioiodine labeled purified soluble antibody-antigen complexes could also be bound to cells derived from freshly harvested TA3/St tumors but not to their in vitro propagated counterparts. Removal of phagocytic or adherent cells from these cell populations decreased the binding of the complexed antibody on freshly harvested TA3/St populations, but did not eliminate it. Inhibition of complexed antibody binding was obtained when TA3/St cells (an H-2a tumor) were pre-incubated with anti-H2a antiserum. Propagation of the tumor in an F1 hybrid (A X C57BL) in which host cells could be distinguished from tumor cells by using an anti H-2b antiserum showed that binding of the immune complex was mostly limited to host cells infiltrating into the tumor population.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1270806

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.

Authors:  Lydie Cassard; Joël F G Cohen-Solal; Annie Galinha; Xavier Sastre-Garau; Claire Mathiot; Jérôme Galon; Thierry Dorval; Alain Bernheim; Wolf H Fridman; Catherine Sautès-Fridman
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

2.  Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.

Authors:  G R Braslawsky; K Kadow; J Knipe; K McGoff; M Edson; T Kaneko; R S Greenfield
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 3.  FcR may function as a progression factor of nonlymphoid tumors.

Authors:  I P Witz; M Ran
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

4.  Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.

Authors:  Joel F G Cohen-Solal; Lydie Cassard; Emilie M Fournier; Shannon M Loncar; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Dermatol Res Pract       Date:  2010-06-28

5.  The tumor microenvironment: the making of a paradigm.

Authors:  Isaac P Witz
Journal:  Cancer Microenviron       Date:  2009-08-23

Review 6.  Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.

Authors:  Elizabeth A Fitzpatrick; Jin Wang; S E Strome
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.